FIELD: medicine.
SUBSTANCE: invention relates to the use of a method for selecting a subject with a GRPR-positive tumour for treatment using a radiolabelled GRPR antagonist, wherein said method comprises selecting a subject for treatment by assessing the accumulation of [68Ga] GRPR antagonist of formula (I) in the lesions as determined by positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) using a radiolabelled GRPR antagonist of formula (I), where M is 68Ga, as a contrast agent, and where at least 30 % of the lesions detected in said subject by conventional imaging, for example, using MRI, CT, SPECT or PET, are also identified by assessing the accumulation of [68Ga]-labelled GRPR antagonist in lesions, as determined by imaging PET/MRI or PET/CT in said subject.
EFFECT: radioactive isotope-labelled GRPR antagonist for use as a therapeutic and diagnostic agent are disclosed.
7 cl, 11 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RADIOPHARMACEUTICALS TARGETING GRPR AND THEIR USE | 2019 |
|
RU2798978C2 |
| STABLE CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | 2020 |
|
RU2839656C1 |
| GRPR ANTAGONISTS FOR DETECTING, DIAGNOSING AND TREATING GRPR-POSITIVE ONCOLOGICAL DISEASE | 2013 |
|
RU2693465C2 |
| RADIOLABELED PROGASTRIN IN CANCER DIAGNOSIS | 2018 |
|
RU2811734C2 |
| DUAL TARGETING COMPOUND, METHOD FOR ITS PREPARATION AND USE | 2022 |
|
RU2838179C2 |
| RADIOPHARMACEUTICAL FOR THE DIAGNOSIS OF PROSTATE CANCER BY POSITRON EMISSION TOMOGRAPHY AND METHOD FOR ITS PRODUCTION | 2022 |
|
RU2796106C1 |
| GRPR ANTAGONISTS FOR DETECTING, DIAGNOSING AND TREATING GRPR-POSITIVE ONCOLOGICAL DISEASE | 2013 |
|
RU2821944C2 |
| PARAMINOHYPURIC ACID (PAH) AS A KIDNEY PROTECTOR | 2020 |
|
RU2804349C2 |
| FAP INHIBITOR | 2019 |
|
RU2797409C2 |
| COMPOUND HAVING TARGETED EFFECT ON PROSTATE-SPECIFIC MEMBRANE ANTIGEN, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2022 |
|
RU2832300C2 |
